Fig. 7 | Signal Transduction and Targeted Therapy

Fig. 7

From: Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence

Fig. 7

Clinical significance of BCL9 genomic alteration in 40 pairs of primary and recurrent HCCs. a Distribution of somatic mutations in BCL9 identified in the recurrent HCC samples. b Calculated BCL9 copy numbers identified in 40 pairs of primary and recurrent HCCs, ***P < 0.001. c Representative BCL9 staining and its density statistics in peritumor tissues, primary tumor tissues with wild-type BCL9, and recurrent tumor tissues with mutant BCL9 (G14E, S278N, and D349V) and BCL9 amplification; scale bars = 50 μm, *P < 0.05, **P < 0.01. d Kaplan−Meier survival analysis showing overall survival rates after the second resection based on BCL9 mutation and copy-number variation in recurrent tumors. e BCL9 copy numbers revealed by qPCR in one normal liver cell line (L0-2) and six HCC cell lines. f BCL9 mRNA and protein levels examined by qRT-PCR and western blot in one normal liver cell line and six HCC cell lines

Back to article page